Page last updated: 2024-12-08

scutellarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

scutellarin: see scutellarein for aglycone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

scutellarin : The glycosyloxyflavone which is the 7-O-glucuronide of scutellarein. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID185617
CHEMBL ID487805
CHEBI ID61278
SCHEMBL ID4211849
MeSH IDM0465605

Synonyms (63)

Synonym
AC-6073
27740-01-8
breviscapin
breviscapine
4h-1-benzopyran-4-one, 7-(.beta.-d-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-
(2s,3s,4s,5r,6s)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid
scutellarin
MEGXP0_000554
beta-d-glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-1-benzopyran-7-yl
scutellarin b
scutellarein 7-beta-d-glucuronide
scutellarein 7-o-beta-d-glucuronide
flavone, 4',5,6,7-tetrahydroxy-, 7-beta-d-glucopyranuronoside
bdbm50242284
CHEMBL487805 ,
chebi:61278 ,
scutellarein-7beta-d-glucuronide
5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-7-yl beta-d-glucopyranosiduronic acid
scutellarein-7-o-beta-d-glucuronide
scutellarein-7-glucuronide
scutellarein-7beta-d-glucuronoside
(2s,3s,4s,5r,6s)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
unii-16igp0ml9a
16igp0ml9a ,
glucopyranosiduronic acid, 5,6-dihydroxy-2-(p-hydroxyphenyl)-4-oxo-4h-1-benzopyran-7-yl, beta-d-
A819175
7-(beta-d-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
116122-36-2
dengzhanhua
new-breviscapine
S3810
AKOS016009652
scutellarein 7-.beta.-d-glucuronoside
scutellarein 7-o-.beta.-glucuronide
glucopyranosiduronic acid, 5,6-dihydroxy-2-(p-hydroxyphenyl)-4-oxo-4h-1-benzopyran-7-yl, .beta.-d-
scutellarein glucuronide [who-dd]
s-7-g
scutellarein 7-.beta.-d-glucuronide
scutellarein glucuronide [mi]
.beta.-d-glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-1-benzopyran-7-yl
1329-06-2
scutellarein 7-o-.beta.-d-glucuronide
flavone, 4',5,6,7-tetrahydroxy-, 7-.beta.-d-glucopyranuronoside
SCHEMBL4211849
Q-100351
scutellarein 7-o-glucuronide
(2s,3s,4s,5r,6s)-6-((5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-7-yl)oxy)-3,4,5-trihydroxytetrahydro-2h-pyran-2-carboxylic acid
CS-4273
HY-N0751
scutellarin, analytical standard
scutellarine
mfcd01861503
(2s,3s,4s,5r,6s)-6-(5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-7-yloxy)-3,4,5-trihydroxytetrahydro-2h-pyran-2-carboxylic acid
Q410712
BS-16838
scutellarin,(s)
BCP11536
breviscapin;scutellarein-7-glucuronide;scutellarin b
CCG-269365
CCG-269364
NCGC00480778-01
(2s,3s,4s,5r,6s)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7-yl]oxy-3,4,5-trihydroxy-oxane-2-carboxylic acid
DTXSID101336184

Research Excerpts

Overview

Scutellarin is an active molecule existing in Erigeron breviscapus (vant.) Hand-Mazz. It is a flavonoid with anti-apoptotic, antioxidant and anti-inflammatory effects.

ExcerptReferenceRelevance
"Scutellarin is an active molecule existing in Erigeron breviscapus (vant.) Hand-Mazz. "( Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats.
Lin, LL; Liu, AJ; Liu, JG; Qin, LP; Su, DF; Yu, XH, 2007
)
2.1
"Scutellarin (SC) is a natural flavonoid with a cardiovascular protective function."( Scutellarin suppresses triple-negative breast cancer metastasis by inhibiting TNFα-induced vascular endothelial barrier breakdown.
Ji, LL; Jia, WY; Lu, B; Mei, XY; Wang, MN; Zhang, JN; Zhang, TY, 2022
)
2.89
"Scutellarin (SCU) is a natural polyphenolic flavonoid that exerts a cardioprotective effect."( Scutellarin attenuates doxorubicin-induced oxidative stress, DNA damage, mitochondrial dysfunction, apoptosis and autophagy in H9c2 cells, cardiac fibroblasts and HUVECs.
Chi, M; Guo, C; Han, Y; Huo, Y; Sun, X; Xin, B; Yang, Q; Zhou, L, 2022
)
2.89
"Scutellarin (SCU) is an important monomer extracted from"( Scutellarin Improves Type 2 Diabetic Cardiomyopathy by Regulating Cardiomyocyte Autophagy and Apoptosis.
Fan, X; Li, S; Li, Z; Su, Y; Tian, M, 2022
)
2.89
"Scutellarin (SC) is a natural chemotherapeutic agent isolated from Erigeron breviscapus with a variety of biological activities."( Scutellarin-mediated autophagy activates exosome release of rat nucleus pulposus cells by positively regulating Rab8a via the PI3K/PTEN/Akt pathway.
Cheng, HX; Hu, SQ; Jiang, YQ; Li, XL; Wang, HR; Zhang, QC; Zou, YP, 2022
)
2.89
"Scutellarin (SL) is a glucuronide flavonoid that has apoptotic, anti-inflammatory, and anti-tumor properties."( Scutellarin alleviates cerebral ischemia/reperfusion by suppressing oxidative stress and inflammatory responses via MAPK/NF-κB pathways in rats.
Bai, N; Huo, Q; Vijayalakshmi, A; Wang, J; Zhang, X; Zhang, Y; Zhang, Z; Zhao, J, 2022
)
2.89
"Scutellarin is a flavone extracted from certain medicinal plants with anti-inflammatory and anti-oxidative properties."( Scutellarin alleviates lipopolysaccharide-provoked septic nephrotoxicity via attenuation of inflammatory and oxidative events and mitochondrial dysfunction.
Ansari, F; Baluchnejadmojarad, T; Golchoobian, R; Mirahmadi, SM; Roghani, M; Rousta, AM; Shahmohammadi, A; Sharayeli, M, 2023
)
3.07
"Scutellarin is a flavonoid with anti-apoptotic, antioxidant and anti-inflammatory effects."( Protective effects of scutellarin in experimental colitis in rats.
Aksit, D; Aksit, H; Altun, E, 2023
)
1.95
"Scutellarin is a natural flavonoid that has been found to exhibit anti-ischemic effect. "( Scutellarin attenuates hypoxia/reoxygenation injury in hepatocytes by inhibiting apoptosis and oxidative stress through regulating Keap1/Nrf2/ARE signaling.
Jia, L; Wu, H, 2019
)
3.4
"Scutellarin is an herbal flavonoid glucuronide, isolated from the Chinese traditional herb Erigeron breviscapus, has been reported to have anti-inflammatory effect."( Scutellarin ameliorates cartilage degeneration in osteoarthritis by inhibiting the Wnt/β-catenin and MAPK signaling pathways.
Cheng, C; Ding, Z; He, W; Huang, W; Li, L; Li, YT; Liu, F; Lu, W; Shan, WS; Xu, J; Yin, Z, 2020
)
2.72
"Scutellarin (Scu) is a flavonoid purified from Erigeron breviscapus."( Scutellarin protects against myocardial ischemia-reperfusion injury by suppressing NLRP3 inflammasome activation.
Chen, RC; Ma, XY; Sun, GB; Sun, XB; Xu, LJ; Zhu, Y, 2020
)
2.72
"Scutellarin (SCU) is an active ingredient extracted from Erigeron breviscapus (Vant.) Hand.-Mazz."( Scutellarin Suppresses RPMI7951 Melanoma Cell Proliferation by Targeting TOPK.
Ge, R; Liu, W; Lv, S; Mou, K; Mu, X; Wang, L; Zhang, J; Zhang, Z, 2021
)
2.79
"Scutellarin (SCU) is a traditional Chinese medicine used for the treatment of ischaemic cerebrovascular disease, but its clinic applications have been limited due to its poor water solubility, poor bioavailability and short half-life. "( Intranasal administration of brain-targeted HP-β-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia.
Ho, PC; Liu, S, 2017
)
2.12
"Scutellarin is a flavone with established antioxidant, anti-inflammatory, and neuroprotective effects."( Scutellarin alleviates lipopolysaccharide-induced cognitive deficits in the rat: Insights into underlying mechanisms.
Baluchnejadmojarad, T; Roghani, M; Zeinali, H, 2018
)
2.64
"Scutellarin is a flavonoid glycoside having antioxidative stress activity."( Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway.
Bao, L; Fu, Y; Ji, R; Jin, Y; Ma, X; Peng, J; Sun, H; Wang, C; Zhang, X, 2018
)
2.64
"Scutellarin is an herbal flavonoid glucuronide with multiple pharmacological activities."( Clinical benefits and pharmacology of scutellarin: A comprehensive review.
Ma, Q; Wang, L, 2018
)
1.47
"Scutellarin is a naturally flavone glycoside that has been shown to exhibit anti-proliferative and anti-apoptotic activities among various human malignancies. "( Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Chen, J; Cheng, Z; Deng, W; Fan, T; Han, W; Wan, B; Wang, X, 2018
)
3.37
"Scutellarin (SC) is a natural flavonoid."( Scutellarin alleviates blood-retina-barrier oxidative stress injury initiated by activated microglia cells during the development of diabetic retinopathy.
Ji, L; Lu, B; Mei, X; Ouyang, H; Wang, Z; Zhang, T, 2019
)
2.68
"1. Scutellarin is a flavonoid glycoside widely used in the treatment of cardio-cerebrovascular diseases in China. "( Inhibition of CYP3A4 and CYP3A5 expression by scutellarin is not mediated via the regulation of hsa-miR-27a, 27b, 148a, 298 and 451a levels.
Cao, C; Ding, W; Gao, Y; Lai, Y; Zhou, X, 2020
)
1.44
"Scutellarin is a flavonoid isolated from a medicinal herb traditionally used as a potent antiplatelet agent."( Scutellarin Suppresses Platelet Aggregation and Stalls Lesional Progression in Mouse With Induced Endometriosis.
Cai, X; Ding, D; Guo, SW; Liu, X; Zheng, H, 2019
)
2.68
"Scutellarin is an active component found in many traditional Chinese herbs and has been regularly used in anti-inflammatory and antitumour medicine."( Scutellarin inhibits proliferation and invasion of hepatocellular carcinoma cells via down-regulation of JAK2/STAT3 pathway.
Dai, C; Dai, Z; Deng, Y; Hao, Q; Lin, S; Liu, K; Tian, T; Wang, M; Zhai, Z; Zheng, Y; Zhou, L, 2019
)
2.68
"Scutellarin is a flavonoid glycoside extracted from the Chinese herb Erigeron breviscapus."( Role of Scutellarin in Ameliorating Lung Injury in a Rat Model of Bilateral Hind Limb Ischemia-Reperfusion.
Elgendy, HA; Elwan, WM; Ibrahim, MAA, 2019
)
1.67
"Scutellarin is an active flavone extracted from traditional Chinese herb Erigeron breviscapus (Vant.) Hand."( Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway.
Li, CY; Li, G; Shen, S; Wang, Q; Wang, X; Wei, X, 2019
)
2.68
"Scutellarin was shown to be a substrate of MRP2 and used as a probe in the inhibition assay."( Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS).
Lam, CW; Li, L; Yi, T, 2013
)
1.11
"Scutellarin is an important bioactive flavonoid extracted from Erigeron breviscapus (Vant.) Hand-Mazz, and scutellarein is the corresponding aglycone of scutellarin. "( Comparison of inhibition capability of scutellarein and scutellarin towards important liver UDP-glucuronosyltransferase (UGT) isoforms.
Cao, YF; Fang, ZZ; Hong, M; Hu, CM; Ma, GY; Sun, XY; Zhu, ZT, 2014
)
2.09
"Scutellarin is a flavonoid which is widely used for the treatment of cardiovascular diseases."( In vitro inhibitory effects of scutellarin on six human/rat cytochrome P450 enzymes and P-glycoprotein.
Guo, C; Han, YL; Li, B; Li, D; Liu, LY; Lu, J; Yang, QJ; Zhou, ZY, 2014
)
1.41
"Scutellarin is an active flavone from Erigeron breviscapine (vant) Hand Mass. "( Scutellarin suppresses migration and invasion of human hepatocellular carcinoma by inhibiting the STAT3/Girdin/Akt activity.
Bao, T; Chen, H; Chen, L; Fu, B; Ge, J; Guo, Z; Ke, Y; Lei, X; Meng, X; Ni, F; Shi, Z; Tan, Y; Tang, H; Wang, L; Wang, Y; Wei, D; Wu, X; Zhang, C, 2017
)
3.34
"Scutellarin is a flavonoid isolated from a medicinal herb Scutellaria barbata D. "( Scutellarin suppresses growth and causes apoptosis of human colorectal cancer cells by regulating the p53 pathway.
Liu, Y; Wang, Z; Yang, N; Zhang, Y; Zhao, Y, 2017
)
3.34
"Scutellarin is a flavonoid extracted from the traditional Chinese herb, Erigeron breviscapus Hand Mazz. "( Scutellarin-induced endothelium-independent relaxation in rat aorta.
Cai, B; Chu, W; Feng, T; Lu, Y; Niu, H; Pan, Z; Shan, L; Yang, B, 2008
)
3.23
"Scutellarin is a major flavone derived from Herba Erigerontis, a Chinese medicine derived from Erigeron breviscapus, which has been shown here to possess both estrogenic and neuroprotective properties."( Estrogenic and neuroprotective properties of scutellarin from Erigeron breviscapus: a drug against postmenopausal symptoms and Alzheimer's disease.
Bi, CW; Chen, JJ; Cheung, AW; Choi, RC; Dong, TT; Jiang, ZY; Li, J; Tsim, KW; Xie, HQ; Zhu, JT, 2009
)
1.33
"Scutellarin is a flavonoid extracted from a traditional Chinese herb, Erigeron breviscapus Hand Mazz, which has been broadly used in treating various cardiovascular diseases. "( Scutellarin exerts its anti-hypertrophic effects via suppressing the Ca2+-mediated calcineurin and CaMKII signaling pathways.
Lu, YJ; Mei, DH; Pan, ZW; Wang, JH; Xu, CQ; Yang, BF; Zhang, R; Zhang, XY; Zhang, Y, 2010
)
3.25
"Scutellarin (SG) is a bioactive flavonoid used to treat cardiovascular disease. "( Intestinal transport of scutellarein and scutellarin and first-pass metabolism by UDP-glucuronosyltransferase-mediated glucuronidation of scutellarein and hydrolysis of scutellarin.
Ao, H; Qian, Z; Wang, Y; Zheng, Y, 2011
)
2.08
"Scutellarin is a flavonoid extracted from a traditional Chinese herb, Erigeron breviscapus. "( Effects of scutellarin on MUC5AC mucin production induced by human neutrophil elastase or interleukin 13 on airway epithelial cells.
Jiang, DP; Kolosov, VP; Perelman, JM; Zhou, XD, 2011
)
2.2
"Scutellarin is a flavonoid derived from the Erigeron breviscapus (vant.) and has been reported to exhibit neuroprotective properties."( Neuroprotective effects of scutellarin against hypoxic-ischemic-induced cerebral injury via augmentation of antioxidant defense capacity.
Gao, XM; Guo, H; Hu, LM; Kang, LY; Li, H; Liu, Y; Shi, F; Wang, SX; Wang, YL, 2011
)
1.39
"Scutellarin is an efficiency antioxidant."( [Study on effects of scutellarin on scavenging reactive oxygen].
Liu, H; Xu, H; Yang, X; Zhou, L, 2002
)
2.08
"Scutellarin is a natural compound from a Chinese herb. "( The protective action of scutellarin against immunological liver injury induced by concanavalin A and its effect on pro-inflammatory cytokines in mice.
Liu, GT; Tan, ZH; Wei, HL; Yu, LH, 2007
)
2.09

Effects

Scutellarin has a significant effect on scavenging hydroxyl radicals, super oxide anion radicals, hydrogen peroxide, their IC50 are 66 micrograms/ml.

Scutellarin drugs have been recognized as a key item in the national development of essential clinical emergency drugs for treating cardiovascular and cerebrovascular diseases. The market demand for scutellarins is growing rapidly. ScutellarIn has antioxidant, antiapoptotic, and anti-inflammatory activities.

ExcerptReferenceRelevance
"Scutellarin benzyl ester has a remarkable protective effect against myocardial ischemic injury and the protective mechanism may associate with its anti-apoptosis effect by inhibiting cytochrome c release and caspase-3 activation."( Scutellarin benzyl ester partially secured the ischemic injury by its anti-apoptosis mechanism in cardiomyocytes of neonatal rats.
Dai, H; Gu, J; Li, JY; Li, LZ; Liu, H; Yang, LM, 2011
)
3.25
"Scutellarin has a significant effect on scavenging hydroxyl radicals, super oxide anion radicals, hydrogen peroxide, their IC50 are 66 micrograms/ml, 1.3 micrograms/ml and 1.6 micrograms/ml respectively."( [Study on effects of scutellarin on scavenging reactive oxygen].
Liu, H; Xu, H; Yang, X; Zhou, L, 2002
)
2.08
"Scutellarin has significant anti-inflammatory and neuroprotective effects."( Scutellarin alleviates depression-like behaviors induced by LPS in mice partially through inhibition of astrocyte-mediated neuroinflammation.
Feng, B; Liu, SB; Lu, L; Qi, JY; Wang, XS; Yang, F; Yang, LK; Yue, J, 2021
)
2.79
"Scutellarin drugs have been recognized as a key item in the national development of essential clinical emergency drugs for treating cardiovascular and cerebrovascular diseases; therefore, the market demand for scutellarin is growing rapidly. "( Metabolic engineering of Yarrowia lipolytica for high-level production of scutellarin.
Shang, Y; Wei, W; Ye, BC; Zhang, P, 2023
)
2.58
"Scutellarin has been demonstrated to rescue ZEA-induced apoptosis in mouse ovarian granulosa cells (GCs), but its specific targets remain unclear."( Scutellarin targets Wnt5a against zearalenone-induced apoptosis in mouse granulosa cells in vitro and in vivo.
Fan, K; Haseeb, A; Hu, P; Li, H; Sun, N; Sun, P; Sun, Y; Yang, H; Yin, W; Zhang, H; Zhang, Z; Zhong, J, 2024
)
3.61
"Scutellarin has been reported to affect Aβ aggregation."( Dengzhan Shengmai capsules and their active component scutellarin prevent cognitive decline in APP/PS1 mice by accelerating Aβ aggregation and reducing oligomers formation.
An, H; Dou, F; Huang, Y; Lai, Y; Liu, W; Peng, D; Shao, W; Wang, L; Wei, D; Yang, T; Zhang, J; Zhang, S; Zhang, Z, 2020
)
1.53
"Scutellarin has been found to have anti-inflammatory and antioxidant effects in various diseases."( Scutellarin protects against lipopolysaccharide-induced behavioral deficits by inhibiting neuroinflammation and microglia activation in rats.
Bian, HT; Huang, JJ; Liang, L; Wang, GH; Wang, HL; Xiao, L, 2020
)
2.72
"Scutellarin has antioxidant, antiapoptotic, and anti-inflammatory activities."( Metanil yellow promotes oxidative stress, astrogliosis, and apoptosis in the cerebellar cortex of adult male rat with possible protective effect of scutellarin: A histological and immunohistochemical study.
Alabiad, MA; Albackoosh, AAA; Albakoush, KMM; Omira, MMA; Shalaby, AM; Tawfeek, SE, 2021
)
1.54
"Scutellarin benzyl ester has a remarkable protective effect against myocardial ischemic injury and the protective mechanism may associate with its anti-apoptosis effect by inhibiting cytochrome c release and caspase-3 activation."( Scutellarin benzyl ester partially secured the ischemic injury by its anti-apoptosis mechanism in cardiomyocytes of neonatal rats.
Dai, H; Gu, J; Li, JY; Li, LZ; Liu, H; Yang, LM, 2011
)
3.25
"Scutellarin has a significant effect on scavenging hydroxyl radicals, super oxide anion radicals, hydrogen peroxide, their IC50 are 66 micrograms/ml, 1.3 micrograms/ml and 1.6 micrograms/ml respectively."( [Study on effects of scutellarin on scavenging reactive oxygen].
Liu, H; Xu, H; Yang, X; Zhou, L, 2002
)
2.08
"Scutellarin has protective effects for cerebral injury through regulating the expression of NOS isoforms and angiogenic molecules."( Neuroprotective effects of scutellarin on rat neuronal damage induced by cerebral ischemia/reperfusion.
Hu, XM; Zeng, FD; Zhou, MM, 2005
)
2.07

Actions

Scutellarin was able to inhibit the activation of NF-kappaB induced by high glucose in ECV304 cells. It could suppress c-Myc protein levels through decreasing LINC00857 expression in osteosarcoma. Such agents will be the next generation anticancer therapeutics.

ExcerptReferenceRelevance
"Scutellarin was shown to suppress the viability of the K562 cells dose-dependently with an IC50 of 6 μM. "( Scutellarin exerts anticancer effects on human leukemia cells via induction of Sub-G1 cell cycle arrest, apoptosis and also inhibits migration and invasion by targeting Raf/MEK/ERK signalling pathway.
Bao, J; Xia, L; Xia, R; Zhao, Y,
)
3.02
"Scutellarin may inhibit the hOATP1B3- and rOATP1B2-mediated transport of rosuvastatin in vitro, and exerts a moderate inhibitory effect on the pharmacokinetics of rosuvastatin in rats. "( Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3.
Guo, Y; Liu, J; Xu, Y; Yuan, L; Zhu, H, 2020
)
3.44
"Scutellarin could suppress c-Myc protein levels through decreasing LINC00857 expression in osteosarcoma."( EGR1 promoted anticancer effects of Scutellarin via regulating LINC00857/miR-150-5p/c-Myc in osteosarcoma.
Han, J; Huang, Y; Li, X; Wang, P; Xia, X; Zhang, H; Zhang, L; Zhao, W, 2021
)
1.62
"Scutellarin can inhibit the growth and migration of tongue cancer cells in vitro and can regulate cell adhesion; such agents will be the next generation anticancer therapeutics. "( Scutellarin inhibits the growth and invasion of human tongue squamous carcinoma through the inhibition of matrix metalloproteinase-2 and -9 and αvβ6 integrin.
Chen, Y; Gao, Z; Huang, D; Li, H; Zhang, L; Zheng, J, 2013
)
3.28
"Scutellarin can inhibit HCC cell metastasis in vivo, and migration and invasion in vitro by down-regulating the STAT3/Girdin/Akt signaling."( Scutellarin suppresses migration and invasion of human hepatocellular carcinoma by inhibiting the STAT3/Girdin/Akt activity.
Bao, T; Chen, H; Chen, L; Fu, B; Ge, J; Guo, Z; Ke, Y; Lei, X; Meng, X; Ni, F; Shi, Z; Tan, Y; Tang, H; Wang, L; Wang, Y; Wei, D; Wu, X; Zhang, C, 2017
)
2.62
"Scutellarin was able to inhibit the activation of NF-kappaB induced by high glucose in ECV304 cells."( Scutellarin isolated from Erigeron multiradiatus inhibits high glucose-mediated vascular inflammation.
Liu, XF; Luo, P; Mo, ZJ; Tan, ZH; Zhang, H; Zhang, ZF, 2008
)
2.51

Treatment

Scutellarin treatment to type 2 diabetic mice ameliorated oxidative stress, inflammatory status and apoptosis in heart. Treatment resulted in decreased levels of reactive oxygen species (ROS) and malondialdehyde (MDA), and increased superoxide dismutase (SOD) activity.

ExcerptReferenceRelevance
"Scutellarin treatment to type 2 diabetic mice ameliorated oxidative stress, inflammatory status and apoptosis in heart."( Scutellarin alleviates type 2 diabetes (HFD/low dose STZ)-induced cardiac injury through modulation of oxidative stress, inflammation, apoptosis and fibrosis in mice.
Aini, M; Cai, R; Gao, Z; Huo, Y; Mijiti, A; Qie, R; Wang, Z, 2021
)
2.79
"Scutellarin treated rats showed improved activity in enzymatic and non-enzymatic antioxidant profile and reversed the content of cytokines compared with MNNG induced gastric cancer group rats."( Chemoprotective Effect of Scutellarin against Gastric Cancer in Rats: An in vitro and in vivo Study.
Meng, M; Sun, J, 2022
)
1.74
"Scutellarin pretreatment effectively lowered kidney function markers (BUN, creatinine, and cystatin C), improved superoxide dismutase (SOD) besides enhancement of level, and/or gene expression for nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and heme oxygenase 1 (HO-1) and also reduced oxidative stress factors including reactive oxygen species (ROS) and malondialdehyde (MDA). "( Scutellarin alleviates lipopolysaccharide-provoked septic nephrotoxicity via attenuation of inflammatory and oxidative events and mitochondrial dysfunction.
Ansari, F; Baluchnejadmojarad, T; Golchoobian, R; Mirahmadi, SM; Roghani, M; Rousta, AM; Shahmohammadi, A; Sharayeli, M, 2023
)
3.8
"Scutellarin treatment resulted in decreased levels of reactive oxygen species (ROS) and malondialdehyde (MDA), and increased superoxide dismutase (SOD) activity in H/R-induced hepatocytes."( Scutellarin attenuates hypoxia/reoxygenation injury in hepatocytes by inhibiting apoptosis and oxidative stress through regulating Keap1/Nrf2/ARE signaling.
Jia, L; Wu, H, 2019
)
2.68
"Scutellarin treatment was applied to male C57BL/6 mice maintained on a high-fat diet (HFD) and HepG2 cells challenged with oleic acid."( Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway.
Bao, L; Fu, Y; Ji, R; Jin, Y; Ma, X; Peng, J; Sun, H; Wang, C; Zhang, X, 2018
)
2.64
"Scutellarin treatment dose-dependently suppressed I/R injury-induced pro-inflammatory cytokine and CK release, oxidative response, loss of mitochondrial membrane potential, and enhanced cell proliferation and anti-oxidant SOD expression."( Scutellarin protects cardiomyocyte ischemia-reperfusion injury by reducing apoptosis and oxidative stress.
Qi, F; Wang, H; Wang, Z; Wu, J; Xu, Z; Yu, J, 2016
)
2.6
"Scutellarin treatment significantly reduced HepG2 cell viability in a dose-dependent manner, and inhibited migration and invasion of HCC cells in vitro."( Scutellarin suppresses migration and invasion of human hepatocellular carcinoma by inhibiting the STAT3/Girdin/Akt activity.
Bao, T; Chen, H; Chen, L; Fu, B; Ge, J; Guo, Z; Ke, Y; Lei, X; Meng, X; Ni, F; Shi, Z; Tan, Y; Tang, H; Wang, L; Wang, Y; Wei, D; Wu, X; Zhang, C, 2017
)
2.62
"In scutellarin-treated HUVECs, a dramatic increase in migration was measured by wound healing assay; Transwell chamber assay found significantly more invading cells in scutellarin-treated groups."( Scutellarin promotes in vitro angiogenesis in human umbilical vein endothelial cells.
Cui, HD; Gao, ZX; Huang, DY; Li, HX; Lv, YH; Zhang, LN; Zheng, JH, 2010
)
2.32
"Scutellarin treatment (at 5, 15, 30 mg/kg, i.p.) increased the AUC(0-∞) by 14.3%, 67.3% and 159.2%, respectively."( Scutellarin inhibits cytochrome P450 isoenzyme 1A2 (CYP1A2) in rats.
Bai, M; Feng, EF; He, GH; He, JC; Jian, TY; Li, HL; Xu, GL, 2012
)
2.54
"Pretreatment with scutellarin significantly reduced histological damage."( Protective effects of scutellarin in experimental colitis in rats.
Aksit, D; Aksit, H; Altun, E, 2023
)
1.55
"Cotreatment with scutellarin significantly decreased the LDH activity (2595.9 ± 72.73), MDA level (1.380 ± 0.06), cTnT concentration (0.0222 ± 0.0041 ng/m L), increased LVEF (76.70 ± 3.91) and LVFS (40.28 ± 3.68)."( Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart.
Guo, C; Han, YL; Huo, Y; Sun, XP; Wan, LL; Yang, QJ, 2017
)
2.23
"Pretreatment of scutellarin retained the EDR of rabbit thoracic aortic rings damaged by DPPH."( Scutellarin protects against vascular endothelial dysfunction and prevents atherosclerosis via antioxidation.
Chen, P; He, B; Li, F; Mo, J; Shen, Z; Yang, R; Zhang, X; Zhang, Y, 2018
)
2.26
"Pretreatment with scutellarin prevented cisplatin-induced decline of renal function including BUN, CRE, and histological damage."( Renoprotective effect of scutellarin on cisplatin-induced renal injury in mice: Impact on inflammation, apoptosis, and autophagy.
Feng, B; Nie, J; Su, ZQ; Sun, CY; Wu, LM; Zhao, J; Zheng, GJ; Zheng, ZL; Zhu, Y, 2019
)
1.14
"Pretreatment with scutellarin decreased the tonic phase, but not the phasic phase of the noradrenaline bitartrate induced tension increment."( Scutellarin-induced endothelium-independent relaxation in rat aorta.
Cai, B; Chu, W; Feng, T; Lu, Y; Niu, H; Pan, Z; Shan, L; Yang, B, 2008
)
2.11
"Pre-treatment with scutellarin, caused the total integral value to decrease in a dose-dependent fashion (3.24 x 10(6), 2.15 x 10(6), 1.84 x 10(6) for groups 10, 50, and 100 uM scutellarin, respectively)."( Effect of scutellarin on nitric oxide production in early stages of neuron damage induced by hydrogen peroxide.
Liu, H; Liu, J; Tang, R; Xu, H; Yang, X, 2005
)
1.05

Toxicity

ExcerptReferenceRelevance
" ④It was impossible to obtain the specific judgment information on the adverse reactions of Breviscapine Injection in the treatment of the disease from the existing evidences."( [Efficacy and safety of Breviscapine Injection in treatment of diabetic nephropathy: systematic review and Meta-analysis of randomized controlled trials].
Yu, DD; Zhao, H; Zhao, J; Zhi, YJ, 2019
)
0.51

Pharmacokinetics

The main pharmacokinetic parameters of scutellarin were as follows: tmax, Cmax, AUC and MRT being (7.5) The aim of this study is to investigate the potential pharmacokinetics interaction between scutellerin and valsartan in rats.

ExcerptReferenceRelevance
" The mean plasma concentration-time curve was protracted and pharmacokinetic parameters were calculated."( [Study on the pharmacokinetics of scutellarin in dogs].
Jiang, XH; Lan, K; Li, SH; Yang, JY; Zhou, J, 2003
)
0.6
"The concentration-time curve of scutellarin can be fitted to a three-compartment model with the main pharmacokinetic parameters as follows: T1/2 gamma, T1/2 alpha and T1/2 beta were (1."( [Study on the pharmacokinetics of scutellarin in dogs].
Jiang, XH; Lan, K; Li, SH; Yang, JY; Zhou, J, 2003
)
0.88
" The main pharmacokinetic parameters showed no significant difference between low and medium doses, but the difference was significant between high dose and other doses."( Study on pharmacokinetics of scutellarin in rabbits.
Chen, H; Lin, AH; Liu, YM; Zeng, FD, 2003
)
0.61
"To establish RP-HPLC method for determination of plasma scutellarin concentration and study of the pharmacokinetic behavior of scutellarin in rat after ig administration of breviscapine and its beta-cyclodextrin complex (breviscapine-beta-CD)."( [Pharmacokinetics of breviscapine and its beta-cyclodextrin complex in rats].
Cao, F; Guo, JX; Ping, QN; Zhang, HY, 2005
)
0.57
" The pharmacokinetic parameters were calculated by 3P97 software."( [Pharmacokinetics of breviscapine and its beta-cyclodextrin complex in rats].
Cao, F; Guo, JX; Ping, QN; Zhang, HY, 2005
)
0.33
" The pharmacokinetic results indicated that scutellarin underwent rapid and extensive biotransformation in vivo."( Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats.
Chen, E; Huang, JM; Huang, XB; Ji, YH; Weng, WY,
)
0.72
" The method herein described was successfully applied for the evaluation of pharmacokinetic profiles of scutellarin guttate pills in 20 healthy volunteers."( Sensitive liquid chromatography-tandem mass spectrometry method for the determination of scutellarin in human plasma: Application to a pharmacokinetic study.
Fang, F; Yulan, S, 2006
)
0.77
"Breviscapine has short half-life after intravenous administration to dogs and rabbits,which show breviscapine is eliminated rapidly and has short action time."( [Pharmacokinetics of breviscapine in dogs and rabbits following single intravenous administration].
Liu, Q; Luo, G; Ma, Y; Wang, Y; Zhang, R, 2005
)
0.33
"Scutellarin was assayed by reverse phase high performance liquid chromatography in various plasma samples after a single dose of 36 mg x kg(-1) iv to each rat, the pharmacokinetic parameters were estimated by 3P97 program."( [Pharmacokinetics and metabolites of scutellarin in normal and model rats].
Gao, HM; Tian, J; Wang, ZM, 2005
)
2.04
"The pharmacokinetic parameters of scutellarin were significantly different in normal and model rats."( [Pharmacokinetics and metabolites of scutellarin in normal and model rats].
Gao, HM; Tian, J; Wang, ZM, 2005
)
0.88
" The mean concentration-time curves of breviscapine liposomes and reference preparation were both fitted to a two-compartment model with the main pharmacokinetic parameters as follows: t(1/2beta) of Breviscapine-LUVs and reference preparation were (42."( Preparation and pharmacokinetics in rabbits of breviscapine unilamellar vesicles.
Guo, J; Li, J; Lv, W; Ping, Q; Wang, X, 2006
)
0.33
" The pharmacokinetic parameters were calculated by 3P97 program and compared by statistic analysis."( [Pharmacokinetics of breviscapine liposomes following intravenous injection in Beagle dogs].
Guo, JX; Li, J; Lo, WL; Ping, QN; Zhang, L; Zhao, CW, 2006
)
0.33
"The mean concentration-time curves of breviscapine liposomes and reference preparation were both fitted to two-compartment model with the main pharmacokinetic parameters as follows: T 1/2 alpha were (4."( [Pharmacokinetics of breviscapine liposomes following intravenous injection in Beagle dogs].
Guo, JX; Li, J; Lo, WL; Ping, QN; Zhang, L; Zhao, CW, 2006
)
0.33
"Compared with the reference preparation, breviscapine liposomes had a much more higher concentration in plasma and contained characteristic of sustained-release, which ameliorated the pharmacokinetic properties of scutellarin."( [Pharmacokinetics of breviscapine liposomes following intravenous injection in Beagle dogs].
Guo, JX; Li, J; Lo, WL; Ping, QN; Zhang, L; Zhao, CW, 2006
)
0.52
" The objectives of this study were to develop methods to identify major metabolites of scutellarin in human urine and plasma and to determine simultaneously the parent drug and its major metabolites in human plasma for pharmacokinetic studies."( Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration.
Chen, X; Cui, L; Duan, X; Ma, B; Zhong, D, 2006
)
0.81
"To investigate the pharmacokinetic and distribution character of scutellarin in plasma and tissues in rats, in order to provide some references for rational drug use in the clinic."( [Pharmacokinetic and tissue distribution study of scutellarin in rats].
Dong, YL; Wang, MY; Xing, JF; You, HS; Zhang, CL, 2007
)
0.83
" The main pharmacokinetic parameters of scutellarin were as follows: tmax, Cmax, AUC and MRT being (7."( [Pharmacokinetic and tissue distribution study of scutellarin in rats].
Dong, YL; Wang, MY; Xing, JF; You, HS; Zhang, CL, 2007
)
0.86
" Coated BVP-PLA-NPs could effectively avoid the capture by the reticuloendothelial system and prolong the half-life of BVP."( Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles.
Li, H; Liu, M; Liu, Q; Luo, G; Wang, Y, 2008
)
0.35
" The pharmacokinetic parameters including area under the curve (AUC), clearance (CL(s)) and volume of distribution (V(c)) were calculated."( Comparative pharmacokinetics of breviscapine liposomes in dogs, rabbits and rats.
Guo, J; Li, J; Lv, W; Ping, Q; Song, Y, 2008
)
0.35
" The pharmacokinetics parameters Cmax and AUC0-8 h of breviscapine were (119."( [The effect of polyamidoamine (PAMAM) dendrimers on the solubility and pharmacokinetics of breviscapine].
Lu, JJ; Ping, QN; Wu, ZH, 2009
)
0.35
"To study the metabolic and pharmacokinetic profile of scutellarin, an active component from the medical plant Erigeron breviscapus (Vant) Hand-Mazz, and to investigate the mechanisms underlying the low bioavailability of scutellarin though oral or intravenous administration in rats."( Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces.
Chen, SY; Dong, Q; Dong, WH; Dong, YL; Lu, J; Wang, MY; Xing, JF; You, HS; Zhu, HF, 2011
)
0.88
" The pharmacokinetic parameters of scutellarin in the urine also showed significant gender differences."( Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces.
Chen, SY; Dong, Q; Dong, WH; Dong, YL; Lu, J; Wang, MY; Xing, JF; You, HS; Zhu, HF, 2011
)
0.91
" The gender differences of pharmacokinetic parameters of scutellarin and scutellarein are due to the higher CL(int) and lower absorption in male rats."( Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces.
Chen, SY; Dong, Q; Dong, WH; Dong, YL; Lu, J; Wang, MY; Xing, JF; You, HS; Zhu, HF, 2011
)
0.88
"To establish a UPLC-MS/MS analysical method for simultaneous determination of concentrations of isoorientin, scutellarin and cynaroside in rat plasma and to study their pharmacokinetic characteristics after intravenous injection of 3 doses of Fufang Hongcao in rats."( [Simultaneous determination of isoorientin, scutellarin and cynaroside in rat plasma and pharmacokinetics by UPLC-MS/MS].
He, F; Huang, Y; Lan, Y; Wang, Y; Zhang, Z; Zheng, L, 2012
)
0.85
"The above men tioned method is so specific, rapid, sensitive that it is suitable for pharmacokinetic studies of Fufang Hongcao injection in rats."( [Simultaneous determination of isoorientin, scutellarin and cynaroside in rat plasma and pharmacokinetics by UPLC-MS/MS].
He, F; Huang, Y; Lan, Y; Wang, Y; Zhang, Z; Zheng, L, 2012
)
0.64
"Scutellarin [scutellarein-7-O-glucuronide (S-7-G)] displayed a unique pharmacokinetic profile in humans after oral administration: the original compound was hardly detected, whereas its isomeric metabolite isoscutellarin [scutellarein-6-O-glucuronide (S-6-G)] had a markedly high exposure."( Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
Chen, X; Gao, C; Guo, Z; You, T; Zhang, H; Zhong, D, 2012
)
2.07
" The aim of this study was to improve the pharmacokinetic profiles of breviscapine using nanostructured lipid carrier based on an ionic complex formation."( Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine.
Gong, T; Li, M; Shan, FY; Zhang, ZR; Zheng, Y; Zhou, J, 2013
)
0.39
" The aim of this study is to investigate the potential pharmacokinetic interaction between scutellarin and valsartan in rats."( Pharmacokinetic interaction between scutellarin and valsartan in rats.
Cui, MY; Ju, AX; Li, QH; Tian, CC; Zhang, CT, 2013
)
0.89
" The pharmacokinetic parameters were calculated with Winnonlin program."( [Pharmacokinetics of scutellarin and its derivant scutellarin ethyl ester in rats].
Feng, J; Gao, HM; Liu, XQ; Meng, QJ; Wang, ZM; Yi, H; Zhu, LW, 2013
)
0.71
" The validated method has been successfully applied to a pharmacokinetic study of breviscapine in rats after intragastric administration at a dose of 20mg/kg."( Simultaneous determination of three glucuronide conjugates of scutellarein in rat plasma by LC-MS/MS for pharmacokinetic study of breviscapine.
Di, X; Liu, Y; Qiu, F; Wang, X; Xia, H, 2014
)
0.4
" The validated method was successfully applied to a pharmacokinetic study of scutellarin and tetrahydropalmatine after oral administration of Deng-yan granule to rats."( Simultaneous determination of scutellarin and tetrahydropalmatine of Deng-yan granule in rat plasma by UFLC-MS/MS and its application to a pharmacokinetic study.
Guan, J; Niu, T; Zhang, X; Zhu, H, 2014
)
0.92
" We conducted a phase I and pharmacokinetic study with the phenolic compound-enriched product extracted from Erigeron breviscapus, Erigerontis hydroxybenzenes injection (EHI), in healthy Chinese volunteers."( Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers.
Dai, GL; Fang, ZY; Ju, WZ; Liu, F; Liu, SJ; Wu, T; Xiong, NN; Zhang, J; Zhao, Y; Zhou, L, 2015
)
0.42
" Information about the pharmacokinetic behavior of the remedy under cerebral I/R injury conditions is lacking."( Pharmacokinetic Comparison of Scutellarin and Paeoniflorin in Sham-Operated and Middle Cerebral Artery Occlusion Ischemia and Reperfusion Injury Rats after Intravenous Administration of Xin-Shao Formula.
Chen, T; Gong, Z; Hu, J; Lan, Y; Li, Y; Liu, T; Lu, Y; Mi, L; Wang, A; Wang, Y; Yang, W; Zheng, J, 2016
)
0.72

Compound-Compound Interactions

Scutellarin is highly likely to participate in drug-drug interactions, as mediated by OATP1B3 in humans. Through this new system combined with molecular biological methods, the changes of metabolites in TCA cycle of BV2 cells can be determined in real-time.

ExcerptReferenceRelevance
"To investigate the effect and mechanism of icariin combined with breviscapine on the erectile function of SHR."( Icariin combined with breviscapine improves the erectile function of spontaneously hypertensive rats.
Cheng, Y; Fan, Z; He, Y; Jiang, J; Jiang, R; Li, Y; Liu, J, 2014
)
0.4
"Icariin combined with breviscapine has synergistic effects on erectile function of SHR through different signal pathways."( Icariin combined with breviscapine improves the erectile function of spontaneously hypertensive rats.
Cheng, Y; Fan, Z; He, Y; Jiang, J; Jiang, R; Li, Y; Liu, J, 2014
)
0.4
"To study the clinical effect of Dengzhanhua injection and Xiongqin injection combined with Xuesaitong to treat the elderly patients with acute cerebral infarction."( [Clinical analysis of acute cerebral infarction by Dengzhanhua injection and Xiongqin injection combined with Xuesaitong treatment].
He, SA; Huang, ZJ; Lei, B, 2014
)
0.4
" The control group were treated using Xuesaitong;The observation group using Dengzhanhua injection and Xiongqin injection combined with Xuesaitong."( [Clinical analysis of acute cerebral infarction by Dengzhanhua injection and Xiongqin injection combined with Xuesaitong treatment].
He, SA; Huang, ZJ; Lei, B, 2014
)
0.4
"Using Dengzhanhua injection and Xiongqin injection combined with Xuesaitong to treat elderly patients with acute cerebral infarction has significantly high curative rate, which can significantly improve patients' cerebral blood flow,plasma viscosity,platelet adhesion rate,nerve function and life skills."( [Clinical analysis of acute cerebral infarction by Dengzhanhua injection and Xiongqin injection combined with Xuesaitong treatment].
He, SA; Huang, ZJ; Lei, B, 2014
)
0.4
" The results suggested that breviscapine have negligible effect on pharmacokinetics of MET in rats; the information may be beneficial for the application of breviscapine in combination with MET in clinical therapy."( Development of a LC-MS/MS method for simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in rat plasma: application to the herb-drug interaction study of metoprolol and breviscapine.
Ma, YR; Qin, HY; Rao, Z; Wang, XD; Wang, YF; Wei, YH; Wu, XA; Zhang, GQ; Zhou, Y, 2015
)
0.42
" Additional, the potential roles of β-glucuronidase (GLU) and OATP2B1 in drug-drug interaction (DDI) between scutellarin and constituents of DZXX were further evaluated in vitro."( β-Glucuronidase- and OATP2B1-mediated drug interaction of scutellarin in Dengzhan Xixin Injection: A formulation aspect.
Gao, J; Huang, H; Huo, X; Lin, W; Lin, Y; Ma, X; Shi, J; Sun, C; Tian, X; Yu, Z; Zhang, B; Zhang, Z, 2020
)
1.01
" Scutellarin is highly likely to participate in drug-drug interactions, as mediated by OATP1B3 in humans."( Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3.
Guo, Y; Liu, J; Xu, Y; Yuan, L; Zhu, H, 2020
)
2.91
" Through this new system combined with molecular biological methods, the changes of metabolites in TCA cycle of BV2 cells and drug metabolism of Scutellarin can be determined in real-time."( Metabolites from scutellarin alleviating deferoxamine-induced hypoxia injury in BV2 cells cultured on microfluidic chip combined with a mass spectrometer.
Chen, S; Fan, F; Li, Y; Lin, JM; Meng, XL; Xu, N; Zeng, J; Zhang, Y, 2023
)
1.45

Bioavailability

Scutellarin (SCU) is a traditional Chinese medicine used for the treatment of ischaemic cerebrovascular disease. Its clinic applications have been limited due to its poor water solubility, poor bioavailability and short half-life.

ExcerptReferenceRelevance
" The relative bioavailability of oral administration was very low, 10."( Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats.
Chen, E; Huang, JM; Huang, XB; Ji, YH; Weng, WY,
)
0.45
"In this report, highly water soluble esters of scutellarin with different molecular weight polyethylene glycol (PEG) were synthesized in order to improve the bioavailability of scutellarin."( [The synthesis, characterization and in situ intestinal absorption of different molecular weight scutellarin-PEG conjugates].
Fan, X; Jiang, X; Li, K; Zhou, Q, 2006
)
0.81
"In an effort to enhance the oral bioavailability of scutellarin, ethyl, benzyl and N,N-diethylglycolamide ester of scutellarin were synthesized."( Prodrugs of scutellarin: ethyl, benzyl and N,N-diethylglycolamide ester synthesis, physicochemical properties, intestinal metabolism and oral bioavailability in the rats.
Cao, F; Guo, JX; Liao, ZG; Ping, QN, 2006
)
0.96
" The efflux of Mrp2, not P-gp, in the intestinal of the rats may be one of the reasons that lead to the low oral bioavailability of scutellarin."( Mrp2-related efflux of scutellarin in the intestinal absorption in rats.
Cao, F; Guo, J; Ping, Q; Zhang, H, 2008
)
0.86
"The objectives of this study were to investigate the effects of mucoadhesive excipients on systemic bioavailability of an inhaled drug and to evaluate the feasibility of using the pulmonary route for non-invasive systemic delivery of scutellarin, a poorly orally absorbed flavonoid glucuronide."( Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats.
Deng, XL; Liao, YH; Liu, CY; Liu, XB; Quan, LH; Yang, M; Ye, JX, 2008
)
0.84
" PAMAM dendrimers can greatly increase the solubility of breviscapine in water and can improve the oral bioavailability of breviscapine significantly."( [The effect of polyamidoamine (PAMAM) dendrimers on the solubility and pharmacokinetics of breviscapine].
Lu, JJ; Ping, QN; Wu, ZH, 2009
)
0.35
"49% of that of blood, respectively, it means that the absorption rate and drug distribution in the brain tissues after intranasal administration were higher than those of oral and tail vein administration."( [Comparison of the distribution of breviscapine in the brain by different administration routes].
Dai, WY; Ge, WH; Li, CY; Shi, SL; Wu, JJ; Xu, LY, 2009
)
0.35
" The multidrug resistance-associated protein may be the second reason for low bioavailability of scutellarin."( [Absorption and transportation characteristics of scutellarin and scutellarein across Caco-2 monolayer model].
Chen, SY; Dong, WH; Dong, YL; Wang, MY; Xing, JF; You, HS; Zhang, HF, 2010
)
0.83
"To study the metabolic and pharmacokinetic profile of scutellarin, an active component from the medical plant Erigeron breviscapus (Vant) Hand-Mazz, and to investigate the mechanisms underlying the low bioavailability of scutellarin though oral or intravenous administration in rats."( Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces.
Chen, SY; Dong, Q; Dong, WH; Dong, YL; Lu, J; Wang, MY; Xing, JF; You, HS; Zhu, HF, 2011
)
0.88
"The results suggest that a large amount of ingested scutellarin was metabolized into scutellarein in the gastrointestinal tract and then excreted with the feces, leading to the extremely low oral bioavailability of scutellarin."( Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces.
Chen, SY; Dong, Q; Dong, WH; Dong, YL; Lu, J; Wang, MY; Xing, JF; You, HS; Zhu, HF, 2011
)
0.89
" A preliminary study in rats also revealed a low bioavailability of S-7-G, as well as a high plasma concentration of S-6-G."( Absorption and disposition of scutellarin in rats: a pharmacokinetic explanation for the high exposure of its isomeric metabolite.
Chen, X; Gao, C; Zhong, D, 2011
)
0.66
"Scutellarein, the main metabolite of scutellarin in vivo, has relatively better solubility, bioavailability and bio-activity than scutellarin."( Synthesis and bio-activity evaluation of scutellarein as a potent agent for the therapy of ischemic cerebrovascular disease.
Ding, AW; Guo, JM; Li, NG; Liu, L; Qian, LH; Song, SL; Tang, H; Tang, YP; Wang, ZJ; Zhang, L, 2011
)
0.64
"Scutellarein, the main metabolite of scutellarin in vivo, has relatively better solubility, bioavailability and bio-activity than scutellarin."( Synthesis and protective effect of scutellarein on focal cerebral ischemia/reperfusion in rats.
Fu, Y; Li, NG; Qian, L; Shen, M; Shi, Q; Tang, H; Tang, Y; Zhang, L, 2012
)
0.65
"Solid self-microemulsifying drug delivery systems (SMEDDS) have been used increasingly for improving the bioavailability of hydrophobic drugs."( Effects of spray-drying and choice of solid carriers on concentrations of Labrasol® and Transcutol® in solid self-microemulsifying drug delivery systems (SMEDDS).
Lam, CW; Li, L; Yi, T, 2013
)
0.39
" However, its poor water solubility and low bioavailability in vivo severely restrict the clinical application."( Solid dispersion tablets of breviscapine with polyvinylpyrrolidone K30 for improved dissolution and bioavailability to commercial breviscapine tablets in beagle dogs.
Cong, W; Feng, Y; Ruan, K; Shen, L; Xu, D; Zhao, L, 2014
)
0.4
" The speed ingested into the blood of scutellarin ethyl ester was faster than scutellarin, and the bioavailability of scutellarin ethyl ester was two times higher than scutellarin."( [Pharmacokinetics of scutellarin and its derivant scutellarin ethyl ester in rats].
Feng, J; Gao, HM; Liu, XQ; Meng, QJ; Wang, ZM; Yi, H; Zhu, LW, 2013
)
0.98
"Breviscapine is used in the treatment of ischemic cerebrovascular diseases, but it has a low bioavailability in the brain due to its poor physicochemical properties and the activity of P-glycoprotein efflux pumps located at the blood-brain barrier."( Mixed polyethylene glycol-modified breviscapine-loaded solid lipid nanoparticles for improved brain bioavailability: preparation, characterization, and in vivo cerebral microdialysis evaluation in adult Sprague Dawley rats.
Aggrey, MO; Fan, L; Guo, L; Guo, X; Li, J; Li, N; Liu, Z; Okeke, CI; Pang, X; Zhang, L; Zhao, H, 2014
)
0.4
"6-fold enhancement in its oral bioavailability in rats."( Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system.
Deng, J; Li, WG; Ning, Q; Yu, DN; Zhou, Y, 2014
)
0.4
" This method seems to effectively enhance the bioavailability of breviscapine in rats."( Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system.
Deng, J; Li, WG; Ning, Q; Yu, DN; Zhou, Y, 2014
)
0.4
" In vivo, the relative bioavailability of breviscapine NE reached to 249."( Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system.
Guan, S; Li, H; Ma, Y, 2015
)
0.42
"The above results suggest that appropriate choice of excipients according to their concentration-dependent and combined effects on MRP2 inhibition can facilitate formulation of SEDDS for improving the bioavailability of drugs that are MRP2 substrates."( Inhibition of human efflux transporter ABCC2 (MRP2) by self-emulsifying drug delivery system: influences of concentration and combination of excipients.
Lam, CW; Li, L; Yi, T, 2014
)
0.4
" However, its poor water solubility and low bioavailability in vivo severely restrict the clinical application."( [Breviscapine listed on progress of new varieties and dosage form research].
Cai, J; Gu, J; Tian, LH; Yu, L; Zhao, LZ, 2014
)
0.4
"Efflux transporters are extensively distributed and expressed in the intestinal epithelium and contribute to the low oral bioavailability of flavonoids and flavonoid glucuronides by pumping these compounds back into intestinal lumen."( A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Chen, M; Lam, CW; Xiao, L; Yi, T; Zhou, H, 2016
)
0.68
" In this study, we formulated and characterized a novel intestinal target nanoparticle carrier based on amphiphilic chitosan derivatives (Chit-DC-VB12) loaded with scutellarin to enhance its bioavailability and then evaluated its therapeutic effect in experimental diabetic retinopathy model."( Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.
Chen, L; Deng, DY; Huang, P; Long, L; Luo, J; Tan, J; Wang, J; Yang, L; Zhang, LM; Zhou, W; Zhu, B, 2017
)
1
" Bioavailability studies were performed in Sprague-Dawley rats, which present the area under the curve of scutellarin of Chit-DC-VB12-Scu was two to threefolds greater than that of free scutellarin alone."( Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.
Chen, L; Deng, DY; Huang, P; Long, L; Luo, J; Tan, J; Wang, J; Yang, L; Zhang, LM; Zhou, W; Zhu, B, 2017
)
1.02
"Chit-DC-VB12 nanoparticles loaded with scutellarin have better bioavailability and cellular uptake efficiency than Scu, while Chit-DC-VB12-Scu nanoparticles alleviated the structural disorder of intraretinal neovessels in the retina induced by diabetes, and it also inhibited the retinal neovascularization via down-regulated the expression of angiogenesis proteins."( Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.
Chen, L; Deng, DY; Huang, P; Long, L; Luo, J; Tan, J; Wang, J; Yang, L; Zhang, LM; Zhou, W; Zhu, B, 2017
)
1.08
"Scutellarin (SCU) is a traditional Chinese medicine used for the treatment of ischaemic cerebrovascular disease, but its clinic applications have been limited due to its poor water solubility, poor bioavailability and short half-life."( Intranasal administration of brain-targeted HP-β-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia.
Ho, PC; Liu, S, 2017
)
2.12
"Drug-loaded MSNs can significantly improve the solubility and bioavailability of BRE, indicating a good application prospect for MSNs in improving the oral absorption of drugs."( Improving Solubility and Bioavailability of Breviscapine with Mesoporous Silica Nanoparticles Prepared Using Ultrasound-Assisted Solution-Enhanced Dispersion by Supercritical Fluids Method.
Chen, M; Li, Q; Li, Z; Wang, R; Wu, F; Yang, G; Yuan, Y; Zhu, H, 2020
)
0.56
" Many methods have been implemented to improve the separation and bioavailability of these compounds from Erigeron breviscapus."( Metabolism and Pharmacological Mechanisms of Active Ingredients in
Cheng, JY; Fan, H; Kang, Q; Lin, P; Wang, J; Zhao, ZL, 2021
)
0.62
" A new drug intranasal delivery system, a nanosuspension-based in situ gel, was developed and evaluated to improve the solubility and bioavailability of the drug and to prolong its retention time in the nasal cavity."( Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine.
Chen, L; Chen, Y; Hu, P; Liu, Y; Xie, J; Yang, M; Yue, P; Zheng, Q, 2020
)
0.56
" Moreover, the absolute bioavailability estimated for BRE-NG after intranasal administration was 57."( Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine.
Chen, L; Chen, Y; Hu, P; Liu, Y; Xie, J; Yang, M; Yue, P; Zheng, Q, 2020
)
0.56

Dosage Studied

In vivo, both Edaravone and Scutellarin markedly reduced the infarct cerebral tissue area. The latter drug was more effective with the dosage used. When used in combination the reduction was more substantial.

ExcerptRelevanceReference
" In aortic thrombus formation in rabbits, the platelet 5-HT release reaction and platelet destruction could be reduced by the compound, meanwhile aortic thrombosis was inhibited with a clear correlation between drug dosage and its efficacy."( [Inhibitory effects of new-breviscapine on thrombosis in vivo].
Wang, ZY, 1989
)
0.28
" The changes of drug concentration in vivo exhibited linear kinetics ove the dosage range of 10-20 mg."( Study on pharmacokinetics of scutellarin in rabbits.
Chen, H; Lin, AH; Liu, YM; Zeng, FD, 2003
)
0.61
" Six Beagle dogs were administrated a single intravenous dosage of 28 mg of breviscapine liposomes and reference preparation, respectively, scutellarin in plasma of 6 dogs at different sampling time was determined by RP-HPLC."( [Pharmacokinetics of breviscapine liposomes following intravenous injection in Beagle dogs].
Guo, JX; Li, J; Lo, WL; Ping, QN; Zhang, L; Zhao, CW, 2006
)
0.54
"The allometric equation might be applied to extroplate dosage for human from animal data and also for dosage adjustment of breviscapine liposomes in order to achieve same AUC as commercial injection."( Comparative pharmacokinetics of breviscapine liposomes in dogs, rabbits and rats.
Guo, J; Li, J; Lv, W; Ping, Q; Song, Y, 2008
)
0.35
"Randomised and quasi-randomised controlled clinical trials of dengzhanhua preparations regardless of duration, dosage and route of administration in patients with confirmed acute cerebral infarction."( Dengzhanhua preparations for acute cerebral infarction.
Cao, W; Liu, G; Liu, W; Wu, T; Zhong, D, 2008
)
0.35
" Preincubation with 300 and 1000 microM SCU significantly suppressed the contractile dose-response to phenylephrine, causing both a significant rise in half maximal effective concentration and a decrease in the maximal developed force."( Nitric oxide and catalase-sensitive relaxation by scutellarin in the mouse thoracic aorta.
Bofferding, A; Lust, RM; Wingard, CJ; Yang, W, 2009
)
0.61
"05 W/cm(2) were used for in vivo and in vitro experiments, respectively, and a very low dosage of scutellarin (15 nM) was used."( Potentiation of scutellarin on human tongue carcinoma xenograft by low-intensity ultrasound.
Cao, W; Fan, H; Li, H; Wang, Z; Zheng, J, 2013
)
0.95
" The Cmax values of SG after dosing with the S nanosuspension were 12."( Nanosuspension development of scutellarein as an active and rapid orally absorbed precursor of its BCS class IV glycoside scutellarin.
Ai, N; Cao, F; Chang, Q; Lee, SMY; Li, S; Miao, X; Yang, X; Zheng, Y, 2014
)
0.61
"In vivo, both Edaravone and Scutellarin markedly reduced the infarct cerebral tissue area with the latter drug being more effective with the dosage used; furthermore, when used in combination the reduction was more substantial."( Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.
Ling, EA; Rangarajan, P; Wu, C; Yuan, Y; Zha, H, 2014
)
0.96
"The results suggest that Edaravone and Scutellarin effectively suppressed the inflammatory responses in activated microglia, with Scutellarin being more efficacious within the dosage range used."( Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.
Ling, EA; Rangarajan, P; Wu, C; Yuan, Y; Zha, H, 2014
)
0.93
" In this article, we reviewed the marketing preparations of breviscapine and its research progress on the new dosage forms."( [Breviscapine listed on progress of new varieties and dosage form research].
Cai, J; Gu, J; Tian, LH; Yu, L; Zhao, LZ, 2014
)
0.4
"Breviscapine can obviously protect the bilateral testes of prepubertal rats after testicular torsion / detorsion by removal of oxygen free radicals and reduction of lipid peroxidation injury, and continuous dosing is even more effective than single-dose medication."( [Breviscapine protects bilateral testes of prepubertal rats after testicular torsion/detorsion].
Gao, L; Hu, XK; Lü, XX; Yao, ML; Zhang, JP, 2016
)
0.43
" The animal model of DR was established from diabetic mellitus (DM) rats by intraperitoneally injected streptozotocin (STZ) at dosage 55 mg/kg."( Network pharmacology mechanism of Scutellarin to inhibit RGC pyroptosis in diabetic retinopathy.
Chen, JL; Gao, AS; Guo, XL; Li, N; Liu, XZ; Wang, TH; Wang, YF; Xiao, YG; Xu, M; Zhang, LC, 2023
)
1.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
proteasome inhibitorA drug that blocks the action of proteasomes, cellular complexes that break down proteins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
glycosyloxyflavoneA member of the class of flavones having one or more glycosyl residues attached at unspecified positions.
glucosiduronic acidAny substance produced by linking glucuronic acid to another substance via a glycosidic bond.
trihydroxyflavoneAny hydroxyflavone carrying three hydroxy groups at unspecified positions.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuraminidase Influenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)52.60000.00000.503510.0000AID366284; AID366285; AID366286
Solute carrier organic anion transporter family member 2B1 Homo sapiens (human)Ki25.90000.53004.11578.4800AID1218884
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)Ki96.60008.50008.50008.5000AID1218896
Substance-P receptorCavia porcellus (domestic guinea pig)IC50 (µMol)50.60000.00002.751810.0000AID366285
5-hydroxytryptamine receptor 7Homo sapiens (human)IC50 (µMol)63.40000.00050.45464.7640AID355721
Substance-K receptorCavia porcellus (domestic guinea pig)IC50 (µMol)50.60000.01500.01500.0150AID366285
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)75.00002.41006.343310.0000AID1218915
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)10.00000.00401.966610.0000AID1218916
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 2B1 Homo sapiens (human)Km43.00000.70005.00608.0900AID1218884
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)Km174.00004.49006.51339.0000AID1218896
UDP-glucuronosyltransferase 1A10Homo sapiens (human)Km225.00002.74004.21005.6800AID1218913
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lipid metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A10Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A10Homo sapiens (human)
fatty acid metabolic processUDP-glucuronosyltransferase 1A8Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A8Homo sapiens (human)
coumarin metabolic processUDP-glucuronosyltransferase 1A8Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A8Homo sapiens (human)
negative regulation of fatty acid metabolic processUDP-glucuronosyltransferase 1A8Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A8Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A8Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A8Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A8Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A8Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A8Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein kinase C bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A8Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A8Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A8Homo sapiens (human)
fatty acid bindingUDP-glucuronosyltransferase 1A8Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A8Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A8Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A8Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A8Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A10Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A10Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A10Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A8Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A8Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A8Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (114)

Assay IDTitleYearJournalArticle
AID1875271Inhibition of MMP7 in human U2OS cells at 5 umol/L by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID1218911Drug metabolism assessed as human recombinant UGT1A8-mediated formation of scutellarein-6,7-diglucuronide after 25 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID722693Neuroprotective activity in rat PC12 cells assessed as inhibition of H2O2-induced cytotoxicity at 25 uM after 3 hrs by MTT assay relative to control2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Design, synthesis and biological evaluation of glucose-containing scutellarein derivatives as neuroprotective agents based on metabolic mechanism of scutellarin in vivo.
AID629629Binding affinity to hen egg white lysozyme at 310 K2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID629621Binding affinity to hen egg white lysozyme assessed as reduction in fluorescence intensity at 1 to 7 x 10'-6 M at 298 K2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID722686Aqueous solubility of the compound by UV-Vis spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Design, synthesis and biological evaluation of glucose-containing scutellarein derivatives as neuroprotective agents based on metabolic mechanism of scutellarin in vivo.
AID722691Neuroprotective activity in rat PC12 cells assessed as inhibition of H2O2-induced cytotoxicity at 50 uM after 3 hrs by MTT assay relative to control2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Design, synthesis and biological evaluation of glucose-containing scutellarein derivatives as neuroprotective agents based on metabolic mechanism of scutellarin in vivo.
AID1218891Ratio of Vmax to Km for drug metabolism in human liver microsomes assessed as formation of scutellarein-6,7-diglucuronide after 7 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID671761Inhibition of SARS coronavirus nsP13 helicase activity expressed in Escherichia coli Rosetta assessed inhibition of DNA unwinding activity at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID718928Absolute bioavailability in po dosed Beagle dog2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Mannich bases of scutellarein as thrombin-inhibitors: design, synthesis, biological activity and solubility.
AID1875270Inhibition of MMP9 in human U2OS cells at 5 umol/L by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID1218916Inhibition of human BCRP-mediated methotrexate transport using inside-out membrane vesicles by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218913Drug metabolism assessed as human recombinant UGT1A10-mediated formation of scutellarein-6,7-diglucuronide after 25 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218889Ratio of Vmax to Km for drug metabolism in human intestinal microsomes assessed as formation of scutellarein-6,7-diglucuronide after 7 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218890Drug metabolism in human liver microsomes assessed as formation of scutellarein-6,7-diglucuronide after 7 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218884Drug uptake assessed as OATP2B1 (unknown origin)-mediated drug transport expressed in HEK293 cells after 7 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1265084N-octanol/0.15 M NaCl partition coefficient, log P of the compound after 5 hrs by spectrophotometric analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1265085N-octanol/0.15 M NaHCO3 partition coefficient, log P of the compound after 5 hrs by spectrophotometric analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1484717Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Scutellarin derivatives as apoptosis inducers: Design, synthesis and biological evaluation.
AID1218941Drug metabolism in human intestinal microsomes assessed as formation of scutellarein-6,7-diglucuronide after 7 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID642415Estrogenic activity at ERalpha in human MVLN cells at 20 ug/mL after 24 hrs by luciferase reporter gene assay relative to E22012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of estrogen receptor α modulators from natural compounds in Si-Wu-Tang series decoctions using estrogen-responsive MCF-7 breast cancer cells.
AID1218894Drug metabolism in rat liver microsomes assessed as formation of scutellarein-6,7-diglucuronide after 7 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218876Drug uptake assessed as human MRP2-mediated drug transport using inside-out membrane vesicles by measuring +ATP/-ATP ratio by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID629620Binding affinity to hen egg white lysozyme assessed as reduction in fluorescence intensity at 1 to 7 x 10'-6 M at 310 K2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID355721Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells2003Journal of natural products, Apr, Volume: 66, Issue:4
Inhibition of [3H]-LSD binding to 5-HT7 receptors by flavonoids from Scutellaria lateriflora.
AID671762Inhibition of HCV NS3 helicase overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of DNA unwinding activity at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID1218879Drug uptake assessed as OATP2B1 (unknown origin)-mediated drug transport expressed in HEK293 cells by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1256186Antithrombotic activity in New Zealand white rabbit platelet poor plasma assessed as increase in activated partial thromboplastin time at 100 uM incubated for 3 mins by coagulometer based assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Synthesis of scutellarein derivatives to increase biological activity and water solubility.
AID1218895Ratio of Vmax to Km for drug metabolism in rat liver microsomes assessed as formation of scutellarein-6,7-diglucuronide after 7 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID629626Binding affinity to hen egg white lysozyme assessed as effective quenching constant at 298 K by Lineweaver-Burk plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1484718Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Scutellarin derivatives as apoptosis inducers: Design, synthesis and biological evaluation.
AID1484719Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Scutellarin derivatives as apoptosis inducers: Design, synthesis and biological evaluation.
AID338974Inhibition of cow milk xanthine oxidase at 50 ug/mL
AID629622Binding affinity to hen egg white lysozyme assessed as Stem-Volmer dynamic quenching constant at 298 K by Stern-Volmer plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1218878Drug uptake assessed as human MRP1-mediated drug transport using inside-out membrane vesicles by measuring +ATP/-ATP ratio by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID629627Binding affinity to hen egg white lysozyme assessed as effective quenching constant at 310 K by Lineweaver-Burk plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1256187Antithrombotic activity in New Zealand white rabbit platelet poor plasma assessed as increase in prothrombin time at 100 uM incubated for 3 mins by coagulometer based assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Synthesis of scutellarein derivatives to increase biological activity and water solubility.
AID722688Anticoagulant activity in New Zealand white rabbit platelet-poor plasma assessed as activated partial thromboplastin time at 100 uM2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Design, synthesis and biological evaluation of glucose-containing scutellarein derivatives as neuroprotective agents based on metabolic mechanism of scutellarin in vivo.
AID722690Anticoagulant activity in New Zealand white rabbit platelet-poor plasma assessed as thrombin time at 100 uM2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Design, synthesis and biological evaluation of glucose-containing scutellarein derivatives as neuroprotective agents based on metabolic mechanism of scutellarin in vivo.
AID1421494Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.
AID1218885Drug uptake assessed as OATP2B1 (unknown origin)-mediated drug transport expressed in HEK293 cells at 0.3 to 10 uM by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID736702Antiadipogenic activity in mouse 3T3L1 cells assessed as downregulation of LPL mRNA expression at 10 to 100 uM after 8 days by RT-PCR analysis2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Scutellarin from Scutellaria baicalensis suppresses adipogenesis by upregulating PPARα in 3T3-L1 cells.
AID1256913Inhibition of human IDH1 expressed in IPTG-induced Escherichia coli BL21 cells assessed as reduction of NADP+ to NADPH after 5 mins by spectrophotometry2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
AID1265081Antioxidant activity in rat PC12 cells assessed as inhibition of H2O2-induced cytotoxicity at 25 uM after 4 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1256192Solubility of compound in water at 0.1 to 10 ug/ml by UV spectrophotometry2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Synthesis of scutellarein derivatives to increase biological activity and water solubility.
AID1218896Drug metabolism assessed as human recombinant UGT1A1-mediated formation of scutellarein-6,7-diglucuronide after 25 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1421493Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.
AID1256189Antioxidant activity assessed as DPPH radical scavenging by spectrophotometric analysis2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Synthesis of scutellarein derivatives to increase biological activity and water solubility.
AID1218874Inhibition of human MDR1-mediated N-methyl quinine formation using inside-out membrane vesicles by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1265079Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1218897Ratio of Vmax to Km for drug metabolism assessed as human recombinant UGT1A1-mediated formation of scutellarein-6,7-diglucuronide after 25 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218892Drug metabolism in rat intestinal microsomes assessed as formation of scutellarein-6,7-diglucuronide after 7 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218883Drug uptake assessed as OATP2B1 (unknown origin)-mediated drug transport expressed in HEK293 cells at 2 uM up to 20 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218873Drug uptake assessed as OAT2 (unknown origin)-mediated drug transport expressed in HEK293 cells by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218915Inhibition of human MRP2-mediated estradiol-17beta-D-glucuronide formation using inside-out membrane vesicles by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1265078Antithrombotic activity in New Zealand white rabbit platelet-poor plasma assessed as increase of fibrinogen at 100 uM after 3 mins (Rvb = 7.02+/- 0.16 g/L)2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1218914Ratio of Vmax to Km for drug metabolism assessed as human recombinant UGT1A10-mediated formation of scutellarein-6,7-diglucuronide after 25 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID629631Binding affinity to hen egg white lysozyme in presence of 2 x10'-3 M2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1875274Inhibition of MMP1 in human U2OS cells at 5 umol/L by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID629623Binding affinity to hen egg white lysozyme assessed as Stem-Volmer dynamic quenching constant at 310 K by Stern-Volmer plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1421495Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.
AID1484720Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Scutellarin derivatives as apoptosis inducers: Design, synthesis and biological evaluation.
AID629625Binding affinity to hen egg white lysozyme assessed as quenching rate constant at 310 K by Stern-Volmer plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID736706Cytotoxicity against mouse 3T3L1 cells assessed as cell viability at < 100 uM after 48 hrs by MTT assay2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Scutellarin from Scutellaria baicalensis suppresses adipogenesis by upregulating PPARα in 3T3-L1 cells.
AID629630Antibacterial activity against Staphylococcus aureus2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID736701Downregulation of C/EBPbeta mRNA expression in mouse 3T3L1 cells at 10 to 100 uM after 8 days by RT-PCR analysis2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Scutellarin from Scutellaria baicalensis suppresses adipogenesis by upregulating PPARα in 3T3-L1 cells.
AID1265082Aqueous solubility of the compound in water after 1 hr by UV-vis spectrophotometer analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1265076Antithrombotic activity in New Zealand white rabbit platelet-poor plasma assessed as increase of prothrombin time at 100 uM after 3 mins (Rvb = 4.99 +/- 0.18 seconds)2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID642414Estrogenic activity at ERalpha in human MVLN cells at 100 ug/mL after 24 hrs by luciferase reporter gene assay relative to E22012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of estrogen receptor α modulators from natural compounds in Si-Wu-Tang series decoctions using estrogen-responsive MCF-7 breast cancer cells.
AID629624Binding affinity to hen egg white lysozyme assessed as quenching rate constant at 298 K by Stern-Volmer plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1875273Inhibition of MMP2 in human U2OS cells at 5 umol/L by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID1265080Antioxidant activity in rat PC12 cells assessed as inhibition of H2O2-induced cytotoxicity at 50 uM after 4 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID366284Inhibition of Influenza A Jinan/15/90 H3N2 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID1218871Drug metabolism in human assessed as retention time of parent compound at 40 mg, po up to 20 hrs by mass defect filter chromatogram analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218893Ratio of Vmax to Km for drug metabolism in rat intestinal microsomes assessed as formation of scutellarein-6,7-diglucuronide after 7 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1265077Antithrombotic activity in New Zealand white rabbit platelet-poor plasma assessed as increase of activated partial thromboplastin time at 100 uM after 3 mins (Rvb = 30.58 +/- 1.55 seconds)2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID722687Anticoagulant activity in New Zealand white rabbit platelet-poor plasma assessed as fibrinogen content at 100 uM2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Design, synthesis and biological evaluation of glucose-containing scutellarein derivatives as neuroprotective agents based on metabolic mechanism of scutellarin in vivo.
AID1218886Drug uptake assessed as OATP2B1 (unknown origin)-mediated drug transport expressed in HEK293 cells at 0.3 to 30 uM by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID736704Antiadipogenic activity in mouse 3T3L1 cells assessed as downregulation of PPARgamma mRNA expression after 8 days by RT-PCR analysis2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Scutellarin from Scutellaria baicalensis suppresses adipogenesis by upregulating PPARα in 3T3-L1 cells.
AID1256190Neuroprotective activity against H2O2-induced cytotoxicity in rat PC12 cells assessed as cell viability at 50 uM by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Synthesis of scutellarein derivatives to increase biological activity and water solubility.
AID1256912Inhibition of human IDH1 R132H mutant expressed in IPTG-induced Escherichia coli BL21 cells assessed as oxidation of NADPH to NADP+ after 5 mins by spectrophotometry2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
AID1256191Neuroprotective activity against H2O2-induced cytotoxicity in rat PC12 cells assessed as cell viability at 25 uM by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Synthesis of scutellarein derivatives to increase biological activity and water solubility.
AID629632Antibacterial activity against Staphylococcus aureus in presence of 25 mg/L lysozyme2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID366285Inhibition of Influenza A PR/8/34 H1N1 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID736705Antiadipogenic activity in mouse 3T3L1 cells assessed as decrease in intracellular lipid accumulation incubated for 8 days followed by compound wash out measured for 60 mins by Oil Red O staining-based phase contrast microscopic analysis2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Scutellarin from Scutellaria baicalensis suppresses adipogenesis by upregulating PPARα in 3T3-L1 cells.
AID1218888Ratio of Vmax to Km for drug uptake assessed as OATP2B1 (unknown origin)-mediated drug transport expressed in HEK293 cells by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218917Inhibition of human MRP3-mediated estradiol-17beta-D-glucuronide formation using inside-out membrane vesicles by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID671764Inhibition of HCV NS3 helicase ATP hydrolysis activity overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of inorganic phosphate release by AM/MG-based colometric analysis in the presence of M13 ssDNA2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID736700Antiadipogenic activity in mouse 3T3L1 cells assessed as upregulation of PPARalpha mRNA expression after 8 days by RT-PCR analysis2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Scutellarin from Scutellaria baicalensis suppresses adipogenesis by upregulating PPARα in 3T3-L1 cells.
AID722692Antioxidant activity assessed as inhibition of DPPH-radical production2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Design, synthesis and biological evaluation of glucose-containing scutellarein derivatives as neuroprotective agents based on metabolic mechanism of scutellarin in vivo.
AID1421496Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.
AID1368258Inhibition of PKM2 in human HeLa cells assessed as reduction in cellular glycolytic rate after 6 hrs2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Scutellarin inhibits Hela cell growth and glycolysis by inhibiting the activity of pyruvate kinase M2.
AID1256194Absolute oral bioavailability in Beagle dog2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Synthesis of scutellarein derivatives to increase biological activity and water solubility.
AID1218918Inhibition of human MRP1-mediated estradiol-17beta-D-glucuronide formation using inside-out membrane vesicles by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218875Drug uptake assessed as human BCRP-mediated drug transport using inside-out membrane vesicles by measuring +ATP/-ATP ratio by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218912Ratio of Vmax to Km for drug metabolism assessed as human recombinant UGT1A8-mediated formation of scutellarein-6,7-diglucuronide after 25 mins by HPLC/UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID366286Inhibition of Influenza A Jiangsu/10/2003 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID1265083N-octanol/0.1 M HCl partition coefficient, log P of the compound after 5 hrs by spectrophotometric analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1256185Antithrombotic activity in New Zealand white rabbit platelet poor plasma assessed as prolongation of thrombin time at 100 uM incubated for 3 mins by coagulometer based assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Synthesis of scutellarein derivatives to increase biological activity and water solubility.
AID1218882Drug uptake assessed as OATP2B1 (unknown origin)-mediated drug transport expressed in HEK293 cells at 3 uM by LC-MS/MS analysis in presence of estrone-3-sulfate2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1484721Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Scutellarin derivatives as apoptosis inducers: Design, synthesis and biological evaluation.
AID736703Antiadipogenic activity in mouse 3T3L1 cells assessed as downregulation of C/EBPalpha mRNA expression after 8 days by RT-PCR analysis2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Scutellarin from Scutellaria baicalensis suppresses adipogenesis by upregulating PPARα in 3T3-L1 cells.
AID1875269Inhibition of MMP13 in human U2OS cells at 5 umol/L by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID629628Binding affinity to hen egg white lysozyme at 298 K2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1265075Antithrombotic activity in New Zealand white rabbit platelet-poor plasma assessed as increase of thrombin time at 100 uM after 3 mins (Rvb = 20.25 +/- 1.02 seconds)2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1218880Drug uptake assessed as OATP1B1 (unknown origin)-mediated drug transport expressed in HEK293 cells by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218877Drug uptake assessed as human MRP3-mediated drug transport using inside-out membrane vesicles by measuring +ATP/-ATP ratio by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID1218881Drug uptake assessed as OATP1B3 (unknown origin)-mediated drug transport expressed in HEK293 cells by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID736699Effect on PPARdelta mRNA expression in mouse 3T3L1 cells at 10 to 100 uM after 8 days by RT-PCR analysis2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Scutellarin from Scutellaria baicalensis suppresses adipogenesis by upregulating PPARα in 3T3-L1 cells.
AID1256188Antithrombotic activity in New Zealand white rabbit platelet poor plasma assessed as fibrinogen at 100 uM incubated for 3 mins by coagulometer based assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Synthesis of scutellarein derivatives to increase biological activity and water solubility.
AID1218868Cmax in human at 60 mg, po2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
AID722689Anticoagulant activity in New Zealand white rabbit platelet-poor plasma assessed as prothrombin time at 100 uM2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Design, synthesis and biological evaluation of glucose-containing scutellarein derivatives as neuroprotective agents based on metabolic mechanism of scutellarin in vivo.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (433)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.23)18.7374
1990's3 (0.69)18.2507
2000's104 (24.02)29.6817
2010's222 (51.27)24.3611
2020's103 (23.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.09 (24.57)
Research Supply Index6.11 (2.92)
Research Growth Index6.42 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (1.59%)5.53%
Reviews18 (4.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other416 (94.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]